Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell trans... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/16/2013
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +95 locations
Conditions: Neuroblastoma
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as efaproxiral may make the tumor cells more sensitive to radiation therapy. It is not yet known if chemotherapy combined with radiation therapy is more effective with or without efaproxiral in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2013
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +21 locations
Conditions: Lung Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama +59 locations
Conditions: Ovarian Cancer
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/03/2013
Locations: Arizona Cancer Center, Tucson, Arizona +6 locations
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving paclitaxel and carboplatin with epirubicin is more effective than paclitaxel and carboplatin alone for ovarian epithelial, fallopian tube, or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and carboplatin with or without epirubicin in treating patients who have stage IIB, stage III, or sta... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/01/2013
Locations: St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota +17 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +286 locations
Conditions: Lung Cancer
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
Terminated
This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2013
Locations: Pfizer Investigational Site, Washington, District of Columbia +50 locations
Conditions: Small Cell Lung Carcinoma
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Completed
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/14/2012
Locations: Research Site, Pleven, Not set +49 locations
Conditions: Ovarian Neoplasms, Ovarian Cancer
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Completed
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/21/2012
Locations: GSK Investigational Site, Los Angeles, California +21 locations
Conditions: Ovarian Cancer, Neoplasms, Ovarian
Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Completed
RATIONALE: The general results of combining irinotecan and platin-based chemotherapies have been very encouraging. As the toxicity profile associated with carboplatin is preferable over cisplatin it is our expectation that patients and physicians would prefer to use this combination if it is equally or more efficacious. To date there has been no agreement regarding the optimal combination of these agents. Based on the trials described in the protocol and our experience with carboplatin/irinoteca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2012
Locations: Owensboro Medical Health System, Owensboro, Kentucky +7 locations
Conditions: Lung Cancer
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Completed
A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with paclitaxel and carboplatin for Phase 2 studies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2012
Locations: Local Institution, East Melbourne, Victoria +4 locations
Conditions: Advanced Solid Tumors, Metastatic Solid Tumors
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Completed
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2012
Locations: Montgomery Cancer Center, L.L.C., Montgomery, Alabama +153 locations
Conditions: Non-small Cell Lung Cancer